Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 23Terminated 9Recruiting 6Unknown 5Not yet recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 65Breast 16Head & Neck 11Tumor-Agnostic 2Thoracic 2Other solid neoplasm 2CNS 1

Conditions

Adenocarcinoma 2

Interventions

Standard of Care 4Radiotherapy 4Oxaliplatin 4tislelizumab 3trastuzumab deruxtecan 2pembrolizumab 2cemiplimab 2anlotinib 2Radiation 2Paclitaxel 2Capecitabine 2130-nm albumin-bound paclitaxel 2vedolizumab 1trametinib 1toripalimab 1surufatinib 1ivosidenib 1disitamab vedotin 1coenzyme Q10 1blinatumomab 1Whole Genome Sequencing 1Ursodeoxycholic Acid 1Ultrasonography 1Tretinoin 1Thymopentin 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Respiratory Rate 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Capecitabine × Tumor-Agnostic × Clear all
NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT06942767 2025-04-27

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡